- Original article
- Open Access
Adenosine as cardioprotective in off-pump coronary artery bypass grafting
Ain-Shams Journal of Anesthesiology volume 11, Article number: 35 (2019)
To assess the effect of adenosine as a cardioprotective drug and its role in attenuating ischemia-reperfusion injury during off-pump coronary artery bypass surgery.
Cardioprotective drugs have long been investigated for use during off-pump coronary artery bypass surgery to attenuate ischemia-reperfusion injury and limit hemodynamic instability. Adenosine has been investigated due to its cardioprotective effect that is mediated through A1 and A3 adenosine receptors. Stimulation of these receptors reproduces the infarct-limiting effect of ischemic preconditioning.
After approval of the local ethics committee and informed written consent, fifty patients undergoing elective off-pump coronary artery bypass grafting were prospectively studied. The adenosine group received an infusion of Adenoscan at a rate of 50 μg/kg/min for 15 min. The control group received normal saline at the same rate and volume calculated. Pulmonary artery catheter was introduced through the right internal jugular vein. Cardiac output measurements were obtained. Cardiac index, stroke volume, systemic vascular resistance, pulmonary vascular resistance, right ventricular stroke work index, and left ventricular stroke work index were derived. Hemodynamic measurements were recorded together with blood levels of troponin I and CK-MB fraction to detect perioperative myocardial necrosis. Postoperative duration of mechanical ventilation, ICU stay together with inotropic support quantification using inotropic score were recorded.
Fifty patients were included in the study. In the adenosine group, the infusion of adenosine resulted in a significant reduction in mean pulmonary artery pressure after stopping drug infusion (18 ± 2.2 mmHg versus 31 ± 4.1 mmHg). There was a recorded increase in cardiac index in the adenosine group that started 15 min after adenosine infusion and lasted for 12 h postoperatively (p < 0.001). Also, adenosine infusion resulted in a reduction in pulmonary vascular resistance that exceeded the reduction in systemic vascular resistance which resulted in a decrease in pulmonary vascular resistance/systemic vascular resistance ratio (0.14 in adenosine group 15 min after injection versus 0.28 in control group) and (0.11 in adenosine group 12 h postoperatively versus 0.26 in control group). The cTroponin I measured 6 h postoperatively was less in the adenosine group compared with the control group (5.8 ± 2.8 ng/ml versus 16.5 ± 3.9 ng/ml).
Adenosine infusion during off-pump coronary artery surgery may improve cardiac index, reduce the need for inotropes, and have cardioprotective effect.
The off-pump coronary artery bypass (OPCAB) graft surgery has been largely extended because of the benefit of avoiding bypass-related cardiopulmonary complications. OPCABG requires a period of coronary artery occlusion to provide a bloodless field. This temporary occlusion of the target arteries may be superimposed on pre-existing ischemia, especially in patients with acute infarction in which blood flow is totally occluded. The off-pump surgical techniques have limited the strategies to protect the heart from ischemia or reperfusion injury, where extracorporeal circulation and cardioplegia are not options. Although many studies have identified effective cardioprotective agents to attenuate ischemia-reperfusion injury, a useful strategy has not been developed for these types of surgeries. Among the various cardioprotective drugs, adenosine has been extensively investigated both in clinical and experimental studies (Vinten-Johansen et al. 2003; Murak et al. 2001). The A1 and A3 adenosine receptors are involved in the endogenous cardioprotective response of adenosine, and their activation reproduces the infarct-limiting effect of ischemic preconditioning (Lasley et al. 1990; Randhawa Jr et al. 1995; Jordan et al. 1997; Auchampach et al. 1997). The present prospective, randomized study was designed to investigate the effect of adenosine pretreatment on hemodynamic instability and myocardial recovery from reperfusion injury in patients undergoing off-pump coronary artery bypass surgery.
After approval of the local ethics committee and informed written consent was obtained from all patients entering the study, 50 patients undergoing off-pump coronary artery bypass grafting were prospectively studied. Only elective operations were included in the study. Patients who were in hemodynamically unstable condition, with poor left ventricular function (ejection fraction ˂ 30%), or who showed evidence of acute ischemia before surgery were excluded from the study. The conduct of anesthesia and operation was similar in all patients. Anesthesia was induced with fentanyl 5–10 μg/kg administered slowly and titrated according to response and sodium thiopental 3–5 mg/kg, and muscular relaxation was obtained with pancuronium bromide 0.1 mg/kg. After sternotomy, the adenosine group (A) patients received an infusion of Adenoscan (Sanofi; Winthrop, France) through a central venous catheter. The adenosine infusion was started at a rate of 50 μg/kg/min, and the infusion lasted for 15 min. During infusion of the drug, if severe hypotension (systolic blood pressure ˂ 60 mmhg) or bradycardia (˂ 50 bpm) developed, the infusion was interrupted, vasopressor drugs were administered, and patient was excluded from the study. The control group (C) received normal saline at the same rate and volume calculated. A standard off-pump coronary artery bypass grafting was undertaken with the left internal mammary artery (LIMA) harvested and from one to three peripheral vein grafts taken in each case from the lower extremities. After systemic heparinization (1 mg/kg), the pericardium was opened. A silastic tape was placed around the left anterior descending (LAD) to produce proximal coronary occlusion, and the epicardial stabilizing device was placed. The LIMA-to-LAD anastomosis was completed. Then, saphenous vein graft was anastomosed to the right coronary artery with the silastic tape and the epicardial stabilizing device. The partial cross-clamp was applied to the aorta for the placement of the proximal anastomoses. Each patient was monitored with five-lead ECG, a radial artery cannula for invasive blood pressure monitoring, and a pulmonary artery catheter (Abbot Laboratories, Chicago, IL) introduced through the right internal jugular vein. The CO measurements were obtained using a thermo dilution catheter. The cardiac index, stroke volume, systemic vascular resistance, pulmonary vascular resistance, right ventricular stroke work index, and left ventricular stroke index were derived. Hemodynamic measurements were recorded after induction of anesthesia, 15 min after stopping injection of the drug, after complete revascularization (removal of the partial clamp), 6 h postoperatively and 12 h after the surgery. To detect perioperative myocardial necrosis, blood levels of troponin I and CK-MB were serially measured by commercially available enzyme-linked immunosorbent assay (Pe-likine Compact; CLB; Amsterdam, Netherlands) after induction of anesthesia, and 6, 12, 24, and 48 h after surgery. At ICU postoperative, data were collected for all patients and this includes the duration of mechanical ventilation and ICU length of stay. The inotropic support for the first 48 h after operation is quantified by the inotropic score; this is calculated as dopamine (× 1) + dobutamine (× 1) + amrinone (× 1) + milrinone (× 15) + epinephrine (× 100) + norepinephrine (× 100) + isoprenaline (× 100) (Wernovsky et al. 1995; Shore et al. 2001; Jin et al. 2007; Jin et al. 2008). The primary outcomes for this study were the effect of adenosine infusion on myocardial protection, the effect on the cardiac index, and inotropic support assessed by inotropic score. The secondary outcome was the effect on the duration of mechanical ventilation and ICU stay in the postoperative period.
Analysis of data was performed by using SPSS version 16 (Chicago IL, USA). Quantitative data were presented as mean ± SD and were statistically analyzed by unpaired student t test. Qualitative data were presented as number and percentages and were statistically analyzed by Chi-square, Fisher’s exact, and Z tests. p value < 0.05 was considered statistically significant, while p value < 0.01 was considered statistically highly significant. Sample size was calculated according to a pilot study on the first 5 patients. By assuming α error = 0.05 (two-tailed) and a power of 80% to detect an assumed clinically significant difference (effect size d = 1.0068) between the measurements of the level of NGAL after 2 h (primary outcome). Twenty-one patients in each group were found to be satisfactory. We considered 24 patients in each group to overcome the dropout.
The study was conducted on 50 patients, 25 patients in each group. Only one patient in the adenosine group, due to some surgical technical reason, was converted to on-pump surgery. The preoperative data and clinical criteria for all patients were similar (Table 1). In adenosine group, there was a slight decrease in the heart rate and in systemic blood pressure which was of no clinical significance as none of the patients experienced a significant hypotension (systolic blood pressure < 60mmhg) or bradycardia (< 50 bpm) during or after infusion of the drug (Figs. 1 and 2). The infusion of adenosine resulted in significant reduction in mean pulmonary artery pressure after stopping drug infusion (18 ± 2.2 mmHg versus 31 ± 4.1 mmHg), after revascularization (17 ± 1.4 mmHg versus 30 ± 3.2 mmHg), after 6 h in ICU (16 ± 2.1 mmHg versus 32 ± 4.5 mmHg), and after 12 h in ICU (19 ± 2.2 mmHg versus 30 ± 3.3 mmHg) compared with control group (Fig. 3). There was a transient decrease in CVP (15 min after drug injection) and in PCWP in adenosine group (after removal of the partial clamp and complete revascularization) (Figs. 4 and 5). The cardiac index was comparable in both groups after induction of anesthesia (p = 0.57), but a slight increase in cardiac index occurred 15 min after adenosine infusion and continued until 12 h postoperatively (p < 0.001) (Fig. 6). The need for inotropic support was significantly lower after adenosine infusion with a much lower inotropic score calculation throughout the study in the adenosine group (Table 2). There was a significant decrease in SVR in adenosine group after injection of drug compared with control group (1142 ± 155 dyne/sec/cm−5 versus 1803 ± 185 dyne/sec/cm−5), after revascularization (1374 ± 155 dyne/sec/cm−5 versus 1880 ± 176 dyne/sec/cm−5), after 6 h in ICU (1343 ± 163 dyne/sec/cm−5 versus 1886 ± 180 dyne/sec/cm−5), and 12 h in ICU (1430 ± 143 dyne/sec/cm−5 versus 1894 ± 168 dyne/sec/cm−5) (Fig. 7). Adenosine has a pulmonary vasodilator effect as there was a significant decrease in PVR after adenosine infusion and this continued until 12 h in ICU when compared with the control group (p < 0.001) (Fig. 8). The adenosine infusion produced much more pulmonary vasodilation than systemic; thus, the PVR/SVR ratio decreased 15 min after adenosine infusion until 12 h postoperatively (Table 3). At the postoperative period, the cTroponin I was less in adenosine group compared with control group (5.8 ± 2.8 ng/ml versus16.5 ± 3.9 ng/ml) in ICU after 6 h, at 12 h (6.0 ± 1.9 ng/ml versus 18.2 ± 1.5 ng/ml), until 48 h (8.9 ± 1.3 ng/ml versus 20.1 ± 0.4 ng/ml) (Fig. 9). Respectively, the CK-MB also was less in adenosine group after 6 h in ICU (40 ± 10 ng/ml versus 75 ± 20 ng/ml), at 12 h (45 ± 12 ng/ml versus 80 ± 15 ng/ml) until the first 24 h (32 ± 17 ng/ml versus 63 ± 19 ng/ml) when compared with control group (Fig. 10).
The results of the present study have shown that pretreatment of adenosine infusion in OPCAB graft surgery resulted in less cTroponin I and CK-MB release, and improved post-bypass CI after the operations. Off-pump coronary artery bypass (OPCAB) graft surgery has been shown to be feasible and effective with nearly comparable postoperative morbidity and mortality rates compared with on-pump cardiac surgery. During OPCABG, reperfusion after a period of coronary artery occlusion is established without any active cardio-protection (i.e., cardioplegia, hypothermia). The main cause of myocardial injury in off-pump surgery is the ligation of the target vessel for 10 to 12 min. In normal myocardium, this transient period of ischemia causes only reversible injury and modest contractile dysfunction; however, in myocardium with preexisting ischemia, it may cause acutely irreversible changes. The myocardial damage may occur during the ligation period or during the post-ligation period when blood flow through the lesion (i.e., stenosis) is restored (Guyton et al. 2000; Cooper et al. 2003). Adenosine has multiple cardioprotective effects on the myocardium and inflammatory response. Cardiologists have introduced the therapeutic use of adenosine to protect the human heart during acute myocardial infarct. Mahaffey and colleagues (Mahaffey et al. 1999) examined the effect of an intravenous adenosine infusion of 70 μg/kg/min for 3 h during acute myocardial infarction. There was a significant reduction in the infarct size in the adenosine group. Quintana and colleagues (Quintana et al. 2003) also demonstrated that an intravenous adenosine infusion reduced cardiac complications in patients with acute anterior wall myocardial infarction. The A1, A2a, and A3 ADO receptors are involved in these cardioprotective effects (Louttit et al. 1999; Shalaby et al. 2008). ADO A1 receptors and possibly A3 receptors are also known to confer protection through inhibitory G-protein-coupled pathways, which is linked to the opening of sarcolemma ATP-sensitive K+ channels (Miura et al. 2000). The mechanism by which opening of these channels elicits cardio-protection is not yet fully elucidated but could involve the reduction of calcium overload or better control of mitochondrial volume and energetics (Peart and Headrick 2007). Other authors (Lasley and Mentzer 1995) have reported that adenosine reduces oxygen-derived free radical production by neutrophils, an effect that could minimize the free radical-induced damage that occurs during reperfusion. Thus, adenosine has a broad spectrum of physiologic effects, which make it suitable as a cardioprotective agent with efficacy in all three windows of opportunity (pretreatment, and during ischemia and reperfusion) and against numerous targets, including the neutrophils (Jin et al. 2007; Lee et al. 1995; Wei et al. 2001; Mentzer Jr et al. 1999; Mentzer Jr et al. 1997; Chauhan et al. 2000; Belhomme et al. 2000). The present results were in line with these previous studies, that adenosine pretreatment exerts a myocellular protective effect against ischemic reperfusion injury, as adenosine pretreatment here resulted in lower release of CK-MB and cTroponin I during the first 48 h of the recovery period with improved recovery in myocardial performance postoperatively, as indicated by faster recoveries of CI. Because of the varied adenosine administration protocols that were applied in different researches designs, there was controversy over the benefits of using adenosine as a cardioprotective agent during these clinical settings. Jin and his colleagues found that 1.5 ml/kg bolus adenosine after the aorta clamp off resulted in less cTnI release and lesser inotropic drug use with shorter ICU stay in a patient undergoing valve replacement (Jin et al. 2007). A study on 30 patients undergoing CABG by Wei et al. proved that the infusion of adenosine (total of 650 μg/kg) before CPB decreased CK-MB release and improved post-bypass CI (Wei et al. 2001). A smaller dose of adenosine (250–350 μg/kg) followed by 5 min of washout before clamp removal in cardiac surgery improved postoperative cardiac function (Lee et al. 1995). Administration of 12 mg or 24 mg adenosine, half before clamp on and half after clamp in CABG patients resulted in greater improvement in postoperative CI and SVI (Chauhan et al. 2000). In this study, the increase in the CI in adenosine is associated with less inotropic agent requirement which indicates that adenosine has a significant myocardial protection effect. This goes in line with previous results (Mentzer Jr et al. 1999; Mentzer Jr et al. 1997) that found a decrease in the requirement of inotropic drugs in adenosine groups. However, contrary to this, Belhomme and his colleagues found no benefit for adenosine 140 mg/kg/min followed by 10 min of washout in CABG patients (Belhomme et al. 2000). The pulmonary vasodilator effect of adenosine is based on the fact that adenosine is metabolized by adenosine deaminase found in vascular endothelial cells and in erythrocytes. Adenosine produced pulmonary vasorelaxation and then metabolized during the passage through the lungs before reaching the systemic circulation (Utterback et al. 1994). The pulmonary clearance of adenosine is dose dependent, at low concentration the adenosine clearance is nearly complete but infusion at high concentration produced systemic vasodilatation. When infused at 75 μg/kg/min, the extraction ratio of adenosine through the pulmonary circulation is approximately 80%, and this ratio fell at higher concentration (Fullerton et al. 1996). Previous study on patients with primary pulmonary hypertension infusion of 50 μg/kg/min adenosine lowered the PVR without significantly fall in SVR (Morgan et al. 1991). Larger dose of adenosine (100 μg/kg/min) was used to produce controlled deliberate systemic hypotension in peripheral vascular surgery and in neurosurgical procedures (Owall et al. 1988; Owall et al. 1987). Because the cardiac index increased after adenosine infusion, the calculated systemic vascular resistance was significantly decreased throughout the study despite transient decreases in mean arterial pressure. However, it would appear that adenosine preferentially vasodilates the pulmonary system, as the ratio of PVR to SVR fell significantly in the adenosine group.
This study concludes that the use of adenosine infusion during off-pump coronary artery bypass surgery may have a cardioprotective effect and may improve myocardial recovery from reperfusion injury.
Availability of data and materials
Data supporting findings can be obtained from the corresponding author.
Off-pump coronary artery bypass
Left internal mammary artery
Left anterior descending artery
Intensive care unit
Central venous pressure
Pulmonary capillary wedge pressure
Systemic vascular resistance
Pulmonary vascular resistance
Pulmonary vascular resistance to systemic vascular resistance ratio
Creatine kinase isoenzyme
Stroke volume index
Auchampach JA, Rizvi A, Qiu Y, Tang XL, Maldonado C, Teschner S, Bolli R (1997) Selective activation of A3 adenosine receptors with N6-(3-iodobenzyl)adenosine-59-N-methyluronamide protects against myocardial stunning and infarction without hemodynamic changes in conscious rabbits. Circ Res 80:800–809
Belhomme D, Peynet J, Florens E, Tibourtine O, Kitakaze M, Menasche P (2000) Is adenosine preconditioning truly cardioprotective in coronary artery bypass surgery? Ann Thorac Surg 70:590–594
Chauhan S, Wasir HS, Bhan A, Rao BH, Saxena N, Venugopal P (2000) Adenosine for cardioplegic induction: a comparison with St Thomas solution. J Cardiothorac Vasc Anesth 14:21–24
Cooper WA, Corvera JS, Thourani VH, Puskas JD, Craer JM, Lattouf OM, Guyton RA (2003) Perfusion-Assisted Direct Coronary Artery Bypass Provides Early Reperfusion of Ischemic Myocardium and Facilitates Complete Revascularization. Ann Thorac Surg 75:1132–1139
Fullerton DA, Jones SD, Grover FL, McIntyre RC (1996) Adenosine effectively controls pulmonary hypertension after cardiac surgery. Ann Thorac Surg 61:1118–1124
Guyton RA, Thourani VH, Puskas JD et al (2000) Perfusion assisted direct coronary artery bypass: selective graft perfusion in off-pump cases. Ann Thorac Surg 69:171–175
Jin ZX, Zhang SL, Wang XM, Bi SH, Xin M, Zhou JJ, Cui Q, Duan WX, Wang HB, Yi DH (2008) The myocardial protective effects of a moderate-potassium adenosine-lidocaine cardioplegia in pediatric cardiac surgery. J Thorac Cardiovasc Surg 136:1450–1455
Jin ZX, Zhou JJ, Xin M, Peng DR, Wang XM, Bi SH, Wei XF, Yi DH (2007) Postconditioning the human heart with adenosine in heart valve replacement surgery. Ann Thorac Surg 83:2066–2072
Jordan JE, Zhao ZQ, Sato H, Taft S, Vinten-Johansen J (1997) Adenosine A2 receptor activation attenuates reperfusion injury by inhibiting neutrophil accumulation, superoxide generation and coronary endothelial adherence. J Pharmacol Exp Ther 280:301–309
Lasley RD, Mentzer RM (1995) Protective effects of adenosine in the reversibly injured heart. Ann Thorac Surg 60:843–846
Lasley RD, Rhee JW, Van Wylen DGL, Mentzer RM Jr (1990) Adenosine A1 receptor mediated protection of the globally ischemic isolated rat heart. J Mol Cell Cardiol 22:39–47
Lee HT, LaFaro R, Reed GE (1995) Pretreatment of human myocardium with adenosine during open heart surgery. J Card Surg 10:665–676
Louttit JB, Hunt A, Maxwell M, Drew G (1999) The time course of cardioprotection induced by GR79236, a selective adenosine A1-receptor agonist, in myocardial ischaemia-reperfusion injury in the pig. J Cardiovasc Pharmacol 33:285–291
Mahaffey KW, Puma JA, Barbagelata NA et al (1999) Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebocontrolled trial: the Acute Myocardial Infarction study of adenosine (AMISTAD) trial. J Am Coll Cardiol 34:1711–1720
Mentzer RM Jr, Birjiniuk V, Khuri S, Lowe JE, Rahko PS, Weisel RD, Wellons HA, Barker ML, Lasley RD (1999) Adenosine myocardial protection: preliminary results of a phase II clinical trial. Ann Surg 229:643–649 discussion 649—650
Mentzer RM Jr, Rahko PS, Molina-Viamonte V, Canver CC, Chopra PS, Love RB, Cook TD, Hegge JO, Lasley RD (1997) Safety, tolerance, and efficacy of adenosine as an additive to blood cardioplegia in humans during coronary artery bypass surgery. Am J Cardiol 79(12A):38–43
Miura T, Liu Y, Kita H, Ogawa T, Shimamoto K (2000) Roles of mitochondrial ATPsensitive K channels and PKC in anti-infarct tolerance afforded by adenosine A1 receptor activation. J Am Coll Cardiol 35:238–245
Morgan JM, McCormack DG, Griffiths MJD, Morgan BM, Barnes PJ, Enans TW (1991) Adenosine as a vasodilator in primary pulmonary hypertension. Circulation 84:1145–1149
Murak S, Morris CD, Budde JM, Velez DA, Zhao ZQ, GuytonRA V-JJ (2001) Experimental off-pump coronary aertry revascularization with adenosine-enhanced reperfusion. J Thorac Cardiovasc Surg 121:570–579
Owall A, Gordon E, Largerkranser M, Lindquist C, Rudehill A, Sollevi A (1987) Clinical experience with adenosine for controlled hypotension during cerebral aneurysm surgery. Anesth Analg 66:229–234
Owall A, Jarnberg PO, Brodin LA, Sollevi A (1988) Effects of adenosine-induced hpotension on myocardial hemodynamics and metabolism in fentanyl anesthetized patients with peripheral vascular disease. Anesthesiology 68:416–210
Peart JN, Headrick JP (2007) Adenosinergic cardioprotection: multiple receptors, multiple pathways. Pharmacol Ther 114:208–221
Quintana M, Hjemdahl P, Sollevi A et al (2003) Left ventricular function and cardiovascular events following adjuvant therapy with adenosine in acute myocardial infarction treated with thrombolysis, results of the ATTenuation by Adenosine of Cardiac Complications (ATTACC) study. Eur J Clin Pharmacol 59:1–9
Randhawa MPS Jr, Lasley RD, Mentzer RM (1995) Effects of exogenous adenosine administration on in vivo myocardial stunning. J Thorac Cardiovasc Surg 110:63
Shalaby A, Rinne T, Jarvinen O, Saraste A, Laurikka J, Porkkala H, Saukko P, Tarkka M (2008) Initial results of a clinical study: adenosine enhanced cardioprotection and its effect on cardiomyocytes apoptosis during coronary artery bypass grafting. Europ J Cardio-Thorac Surg 33:639–644
Shore S, Nelson DP, Pearl JM et al (2001) Usefulness of corticosteroid therapy in decreasing epinephrine requirements in critically ill infants with congenital heart disease. Am J Cardiol 88:591–594
Utterback DB, Staples ED, White SE, Hill JA, Belardinelli L (1994) Basis for the selective reduction of pulmonary vascular resistance in humans during infusion of adenosine. J Appl Physiol 76:724–730
Vinten-Johansen J, ZhaoZQ CJS, Morris CD, Budde JM, Thourani VH, Guyton RA (2003) Adenosine in Myocardial Protection in On-Pump and Off-Pump Cardiac Surgery. Ann Thorac Surg 75:S691–S699
Wei M, Kuukasjarvi P, Laurikka J, Honkonen EL, Kaukinen S, Laine S, Tarkka M (2001) Cardioprotective effect of adenosine pretreatment in coronary artery bypass grafting. Chest 120:860–865
Wernovsky G, Wypij D, Jonas RA et al (1995) Postoperative course and hemodynamic profile after the arterial switch operation in neonates and infants. A comparison of low-flow cardiopulmonary bypass and circulatory arrest. Circulation 92:2226–2235
Ethics approval and consent to participate
Local ethics approval committee has been obtained, and written informed consent has been obtained from all patients enrolled in the study. This study has been approved by “Ain Shams University, Faculty of Medicine Research Ethics Committee” (REC).
Approval number: FMASU R 49/2019
Date of approval: 28 August 2019
Consent for publication
The authors declare that they have no competing interests.
About this article
Cite this article
Aziz, M.M.A., Hamid, A.M.A. & Hamid, H.M.A. Adenosine as cardioprotective in off-pump coronary artery bypass grafting. Ain-Shams J Anesthesiol 11, 35 (2019). https://doi.org/10.1186/s42077-019-0049-3
- Off-pump coronary artery surgery
- Cardiac index
- Ischemic preconditioning